SG10201609131YA - Zinc-pga compositions and methods for treating cancer - Google Patents

Zinc-pga compositions and methods for treating cancer

Info

Publication number
SG10201609131YA
SG10201609131YA SG10201609131YA SG10201609131YA SG10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA
Authority
SG
Singapore
Prior art keywords
methods
tumors
compositions
zinc
tumor
Prior art date
Application number
SG10201609131YA
Other languages
English (en)
Inventor
Fred Chung Jinhyuk
Original Assignee
Xylonix Ip Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylonix Ip Holdings Pte Ltd filed Critical Xylonix Ip Holdings Pte Ltd
Priority to SG10201609131YA priority Critical patent/SG10201609131YA/en
Priority to SG11201903753QA priority patent/SG11201903753QA/en
Priority to PCT/SG2017/050545 priority patent/WO2018084806A1/en
Priority to CA3042383A priority patent/CA3042383A1/en
Priority to US16/346,286 priority patent/US11944640B2/en
Priority to KR1020197015744A priority patent/KR102616690B1/ko
Priority to MX2019005104A priority patent/MX395613B/es
Priority to AU2017354787A priority patent/AU2017354787B2/en
Priority to EP17798014.1A priority patent/EP3534914B1/en
Priority to SG10202013112YA priority patent/SG10202013112YA/en
Priority to JP2019545869A priority patent/JP7083835B2/ja
Priority to CN202310311382.9A priority patent/CN116350658A/zh
Priority to CN201711108631.5A priority patent/CN108014131B/zh
Publication of SG10201609131YA publication Critical patent/SG10201609131YA/en
Priority to MX2022011372A priority patent/MX2022011372A/es
Priority to JP2022089345A priority patent/JP7466822B2/ja
Priority to AU2023203220A priority patent/AU2023203220B2/en
Priority to US18/623,943 priority patent/US20250025496A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201609131YA 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer SG10201609131YA (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer
AU2017354787A AU2017354787B2 (en) 2016-11-01 2017-10-31 Zinc-gamma-PGA compositions and methods for treating cancer
JP2019545869A JP7083835B2 (ja) 2016-11-01 2017-10-31 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法
CA3042383A CA3042383A1 (en) 2016-11-01 2017-10-31 Zinc-.gamma.-pga compositions and methods for treating cancer
US16/346,286 US11944640B2 (en) 2016-11-01 2017-10-31 Zinc-[gamma]-PGA compositions and methods for treating cancer
KR1020197015744A KR102616690B1 (ko) 2016-11-01 2017-10-31 아연-γ-PGA 조성물 및 암을 치료하기 위한 방법
MX2019005104A MX395613B (es) 2016-11-01 2017-10-31 COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.
SG11201903753QA SG11201903753QA (en) 2016-11-01 2017-10-31 Zinc-?-pga compositions and methods for treating cancer
EP17798014.1A EP3534914B1 (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer
SG10202013112YA SG10202013112YA (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer
PCT/SG2017/050545 WO2018084806A1 (en) 2016-11-01 2017-10-31 ZINC-γ-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER
CN202310311382.9A CN116350658A (zh) 2016-11-01 2017-11-01 锌-γ-PGA组合物和治疗癌症的方法
CN201711108631.5A CN108014131B (zh) 2016-11-01 2017-11-01 锌-γ-PGA组合物和治疗癌症的方法
MX2022011372A MX2022011372A (es) 2016-11-01 2019-04-30 Composiciones de zinc-y-pga y metodos para tratar el cancer.
JP2022089345A JP7466822B2 (ja) 2016-11-01 2022-06-01 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法
AU2023203220A AU2023203220B2 (en) 2016-11-01 2023-05-23 Zinc-gamma-pga compositions and methods for treating cancer
US18/623,943 US20250025496A1 (en) 2016-11-01 2024-04-01 Zinc-[gamma]-pga compositions and methods for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
SG10201609131YA true SG10201609131YA (en) 2018-06-28

Family

ID=60327362

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer
SG11201903753QA SG11201903753QA (en) 2016-11-01 2017-10-31 Zinc-?-pga compositions and methods for treating cancer
SG10202013112YA SG10202013112YA (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201903753QA SG11201903753QA (en) 2016-11-01 2017-10-31 Zinc-?-pga compositions and methods for treating cancer
SG10202013112YA SG10202013112YA (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer

Country Status (10)

Country Link
US (2) US11944640B2 (cg-RX-API-DMAC7.html)
EP (1) EP3534914B1 (cg-RX-API-DMAC7.html)
JP (2) JP7083835B2 (cg-RX-API-DMAC7.html)
KR (1) KR102616690B1 (cg-RX-API-DMAC7.html)
CN (2) CN108014131B (cg-RX-API-DMAC7.html)
AU (2) AU2017354787B2 (cg-RX-API-DMAC7.html)
CA (1) CA3042383A1 (cg-RX-API-DMAC7.html)
MX (2) MX395613B (cg-RX-API-DMAC7.html)
SG (3) SG10201609131YA (cg-RX-API-DMAC7.html)
WO (1) WO2018084806A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197246A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates
US11944640B2 (en) 2016-11-01 2024-04-02 Xylonix PTE. LTD. Zinc-[gamma]-PGA compositions and methods for treating cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
KR20210024065A (ko) * 2018-06-22 2021-03-04 자일로닉스 아이피 홀딩스 피티이. 엘티디. 아연 제제를 이용한 종양학 치료
KR102094182B1 (ko) * 2018-06-28 2020-03-30 주식회사 알랙스탠드 아연 함유 수용성 폴리글루타믹산 복합체 조성물

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897122A (en) 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
JP2712583B2 (ja) 1989-06-28 1998-02-16 味の素株式会社 易吸収性ミネラル含有飲食物
JP3551149B2 (ja) 1992-03-24 2004-08-04 味の素株式会社 易吸収性ミネラル含有組成物及びそれを含有する飲食品
EP0605757B1 (en) 1992-11-25 2001-08-16 Ajinomoto Co., Inc. Compositions and goods containing minerals and poly-gamma-glutamic acid
US5447732A (en) 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
ITMI950515A0 (it) 1995-03-16 1995-03-16 Valpharma Sa Formulazioni gastroresistenti contenenti zinco
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH11313618A (ja) 1998-05-06 1999-11-16 Yoshio Inoue 胃にやさしい家畜用ミネラル（亜鉛）製剤及びその製造法
US6462075B1 (en) 1999-12-23 2002-10-08 The University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogensis and related disease states
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
WO2003061598A2 (en) 2002-01-25 2003-07-31 The University Of Georgia Research Foundation, Inc. Solenopsin a, b and analogs as novel angiogenesis inhibitors
WO2004080210A1 (en) 2003-03-14 2004-09-23 Boehringer Ingelheim Danmark A/S Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea
KR100498812B1 (ko) 2003-07-10 2005-07-01 주식회사 바이오리더스 초고분자량의 폴리감마글루탐산을 함유하는 미네랄의 체내흡수 촉진용 조성물
JP4457641B2 (ja) 2003-11-10 2010-04-28 味の素株式会社 ゼラチンカプセル
JP5162812B2 (ja) 2004-07-08 2013-03-13 大正製薬株式会社 亜鉛含有経口投与用組成物
NZ563686A (en) 2005-06-07 2011-07-29 Univ Yale Methods of treating cancer and other conditions or disease states using LFMAU and LDT
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
WO2007043606A1 (ja) 2005-10-12 2007-04-19 Genolac Bl Corporation アニオン性ポリアミノ酸／金属複合体からなる抗糖尿病薬剤
US7528125B2 (en) 2006-03-20 2009-05-05 Jonathan L. Sessler Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
CN101674852A (zh) 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
AU2008251836A1 (en) 2007-05-09 2008-11-20 Salutria Pharmaceuticals, Llc Spiro compounds for treatment of inflammatory disorders
CN101707869A (zh) 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
CA2756942C (en) 2009-04-10 2019-01-08 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CN101716180B (zh) 2009-11-06 2013-04-24 广西强寿药业集团有限公司 一种组合补充锌、钙药物及其制备方法
US20110117210A1 (en) 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
CA2892049C (en) 2012-11-21 2018-09-11 KBS Research, LLC Herbal supplements and methods of use thereof
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
EP2978423A4 (en) 2013-03-28 2016-08-24 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
SG10201913730RA (en) 2013-04-12 2020-03-30 Rebecca Bent Cancer therapy
EP2989115A4 (en) 2013-04-26 2017-01-11 Nitto Denko Corporation A large scale process for preparing poly (glutamyl-glutamate) conjugates
US10398682B2 (en) 2013-07-15 2019-09-03 The Board Of Regents Of The University Of Texas System Methods and compositions to prevent or treat bacterial infections
JP2016069303A (ja) 2014-09-29 2016-05-09 タカラバイオ株式会社 フコイダンを有効成分とする脱毛抑制用組成物
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
WO2016057744A1 (en) 2014-10-08 2016-04-14 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US20160122739A1 (en) 2014-10-31 2016-05-05 Wisconsin Alumni Research Foundation Factor ix variants and methods of use therefor
JP6716464B2 (ja) 2014-12-03 2020-07-01 ノーベルファーマ株式会社 酢酸亜鉛水和物錠及びその製造方法
US20200330557A1 (en) 2016-08-19 2020-10-22 Brooklyn Immunotherapeutics Llc Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
KR20210024065A (ko) 2018-06-22 2021-03-04 자일로닉스 아이피 홀딩스 피티이. 엘티디. 아연 제제를 이용한 종양학 치료

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11944640B2 (en) 2016-11-01 2024-04-02 Xylonix PTE. LTD. Zinc-[gamma]-PGA compositions and methods for treating cancer
WO2022197246A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates

Also Published As

Publication number Publication date
KR102616690B1 (ko) 2023-12-21
CN108014131A (zh) 2018-05-11
JP2022116255A (ja) 2022-08-09
WO2018084806A1 (en) 2018-05-11
JP7083835B2 (ja) 2022-06-13
SG10202013112YA (en) 2021-02-25
EP3534914A1 (en) 2019-09-11
EP3534914B1 (en) 2025-07-16
AU2023203220A1 (en) 2023-06-22
CN108014131B (zh) 2023-04-14
US20250025496A1 (en) 2025-01-23
MX2022011372A (es) 2022-10-10
EP3534914C0 (en) 2025-07-16
US11944640B2 (en) 2024-04-02
CN116350658A (zh) 2023-06-30
CA3042383A1 (en) 2018-05-11
AU2017354787B2 (en) 2023-02-23
MX2019005104A (es) 2019-10-30
MX395613B (es) 2025-03-25
JP7466822B2 (ja) 2024-04-15
AU2023203220B2 (en) 2025-07-31
KR20190120159A (ko) 2019-10-23
AU2017354787A1 (en) 2019-05-16
US20190255104A1 (en) 2019-08-22
SG11201903753QA (en) 2019-05-30
JP2019534330A (ja) 2019-11-28

Similar Documents

Publication Publication Date Title
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
NZ700759A (en) Combination therapy for treating cancer
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MY162903A (en) Methods of treatment of pancreatic cancer
WO2016133903A3 (en) Combination therapy for cancer treatment
SG10201902664RA (en) Combination therapy for treating cancer
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
AU2018380132A8 (en) Tubulin inhibitors
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
PH12020500666A1 (en) Pladienolide compounds and their use
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
EP3781148A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX382930B (es) Tratamiento con cis-clomifeno de sofocos y pérdida ósea inducidos por privación de andrógeno terapéutica.
SG10201708886RA (en) α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.